SANTA MONICA, Calif. – GoodRx Holdings, Inc. (NASDAQ:), the leading U.S. prescription savings platform, announced the appointment of Scott Wagner as co-chairman of its Board of Directors, effective January 21, 2025. Wagner, who served as the company’s Interim Chief Executive Officer from April 2023 until his recent appointment, brings more of 25 years of experience in executive management to that role. The appointment comes as GoodRx maintains impressive gross profit margins of 94%, and analysts expect positive net income growth this year, according to InvestingPro data.
Wagner’s previous roles include CEO and other executive positions at GoDaddy (NYSE: ), where he was instrumental in the company’s global expansion and revenue growth. He also worked as a partner at the global investment firm KKR. His tenure at GoodRx as interim CEO has been marked by efforts to shape the company’s strategic direction. InvestingPro The analysis reveals that the company operates with moderate levels of leverage and maintains strong liquidity, with current assets significantly exceeding current liabilities.
Trevor Bezdek, co-founder and current co-president of GoodRx, expressed his enthusiasm for Wagner’s new role, citing his deep understanding of the company’s operations and his potential to influence its growth and innovation.
In addition to his responsibilities as Co-Chair, Wagner will chair the Compensation Committee. His appointment coincides with the resignation of Simon Patterson, who resigned on the same day as a director and as a member of the Nomination and Corporate Governance Committee and the Innovation Committee.
GoodRx is known for providing drug cost savings and health information to millions of Americans. It has been credited with saving consumers over $75 billion in prescription costs since its inception in 2011.
The Company encourages investors and potential investors to monitor its press releases, SEC filings and public communications, which are periodically updated on its Investor Relations website.
This announcement is based on a press release from GoodRx Holdings, Inc.
In other recent news, GoodRx has seen significant changes to its executive team, with CFO Karsten Voermann resigning for personal reasons. Romin Nabiey, the current Chief Accounting Officer, will serve as interim CFO. Leerink analyst Michael Cherny maintains a positive outlook for GoodRx despite the sudden resignation, highlighting the company’s Ebitda and cash flow generation.
On a related note, Wendy Barnes, former CEO of RxBenefits, has taken the helm as the new CEO of GoodRx. Barnes’ appointment was greeted with optimism Wells Fargo (NYSE: ) analyst Stan Berenshteyn, who reiterated an Overweight rating on GoodRx.
Despite these positive developments, Raymond (NSE: ) James removed GoodRx from his list of analysts’ favorites, citing the need for more time for the company’s turnaround initiatives to show tangible financial improvements. Similarly, Mizuho (NYSE: ) initiated coverage on GoodRx with a Neutral rating, projecting the company’s 2026 revenue at $860 million, below GoodRx’s target of approximately $1 billion.
Sarah Griffis, the former head of GoodRx, has been named the new CTO of WM Technology, known for managing the cannabis marketplace Weedmaps. This is one of the recent developments for GoodRx, reflecting a period of significant transition and strategic change within the company.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
